MX2022011214A - Composiciones y metodos para el tratamiento de lesion por reperfusion o hemorragia despues de la terapia de recanalizacion. - Google Patents

Composiciones y metodos para el tratamiento de lesion por reperfusion o hemorragia despues de la terapia de recanalizacion.

Info

Publication number
MX2022011214A
MX2022011214A MX2022011214A MX2022011214A MX2022011214A MX 2022011214 A MX2022011214 A MX 2022011214A MX 2022011214 A MX2022011214 A MX 2022011214A MX 2022011214 A MX2022011214 A MX 2022011214A MX 2022011214 A MX2022011214 A MX 2022011214A
Authority
MX
Mexico
Prior art keywords
methods
reperfusion injury
hemorrhage
compositions
treatment
Prior art date
Application number
MX2022011214A
Other languages
English (en)
Spanish (es)
Inventor
Weiqiang Zhan
Byoung Joo Gwag
Chun San An
Jing Yu Jin
Sung Ig Cho
Fangmeng Zhu
Xinliang Xu
Fuxin Liu
Soon-Mi Won
Original Assignee
Gnt Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gnt Pharma Co Ltd filed Critical Gnt Pharma Co Ltd
Publication of MX2022011214A publication Critical patent/MX2022011214A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2022011214A 2020-03-11 2021-03-10 Composiciones y metodos para el tratamiento de lesion por reperfusion o hemorragia despues de la terapia de recanalizacion. MX2022011214A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062988187P 2020-03-11 2020-03-11
PCT/IB2021/000136 WO2021181159A1 (en) 2020-03-11 2021-03-10 Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy

Publications (1)

Publication Number Publication Date
MX2022011214A true MX2022011214A (es) 2022-10-07

Family

ID=77665492

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022011214A MX2022011214A (es) 2020-03-11 2021-03-10 Composiciones y metodos para el tratamiento de lesion por reperfusion o hemorragia despues de la terapia de recanalizacion.
MX2025012439A MX2025012439A (es) 2020-03-11 2022-09-09 Composiciones y metodos para el tratamiento de lesion por reperfusion o hemorragia despues de la terapia de recanalizacion

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2025012439A MX2025012439A (es) 2020-03-11 2022-09-09 Composiciones y metodos para el tratamiento de lesion por reperfusion o hemorragia despues de la terapia de recanalizacion

Country Status (12)

Country Link
US (3) US11826329B2 (https=)
EP (1) EP4117648A4 (https=)
JP (1) JP2023517566A (https=)
KR (1) KR20230010187A (https=)
CN (1) CN115515573A (https=)
AU (1) AU2021233206A1 (https=)
BR (1) BR112022018136A2 (https=)
CA (1) CA3174709A1 (https=)
CO (1) CO2022014343A2 (https=)
IL (2) IL309923A (https=)
MX (2) MX2022011214A (https=)
WO (1) WO2021181159A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12285182B2 (en) 2018-10-10 2025-04-29 Innova Vascular, Inc. Devices and methods for removing an embolus
CN115515573A (zh) 2020-03-11 2022-12-23 Gnt制药有限公司 用于治疗再通疗法之后再灌注损伤或出血的组合物和方法
CN113995723B (zh) 2020-07-27 2025-02-18 浙江普洛家园药业有限公司 一种索法地尔冻干粉针剂的制备方法及其产品和用途
JP2025500716A (ja) * 2021-12-28 2025-01-14 ジーエヌティー ファーマ カンパニー， リミテッド 肺障害を処置するための組成物及び方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1551793B1 (en) * 2002-06-19 2016-01-20 AmKor Pharma, Inc. Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same
KR100522188B1 (ko) * 2003-01-20 2005-10-18 주식회사 뉴로테크 뉴로트로핀에 의해 유도되는 세포괴사 억제 방법
WO2006126825A1 (en) 2005-05-23 2006-11-30 Choongwae Pharma Corporation Composition comprising tetrafluorobenzyl derivatives or salts of thereof for injection
EP1883619B8 (en) * 2005-05-25 2013-05-01 JW Pharmaceutical Corporation Process of preparation of substituted tetrafluorobenzylaniline compound and its pharmaceutically approved salts
KR101523345B1 (ko) * 2008-04-28 2015-05-28 주식회사 지엔티파마 재관류 손상의 치료 또는 예방용 약학 조성물
CN102617383A (zh) 2012-03-20 2012-08-01 横店集团家园化工有限公司 索法地尔晶型、制备方法及包含索法地尔晶体的无菌粉末
AU2016210973B2 (en) 2015-01-27 2019-02-14 Astrazeneca Ab Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction
CN115515573A (zh) 2020-03-11 2022-12-23 Gnt制药有限公司 用于治疗再通疗法之后再灌注损伤或出血的组合物和方法

Also Published As

Publication number Publication date
WO2021181159A1 (en) 2021-09-16
CA3174709A1 (en) 2021-09-16
EP4117648A4 (en) 2024-05-29
BR112022018136A2 (pt) 2022-10-25
EP4117648A1 (en) 2023-01-18
IL296288B2 (en) 2024-06-01
KR20230010187A (ko) 2023-01-18
IL296288A (en) 2022-11-01
US11826329B2 (en) 2023-11-28
US20260027076A1 (en) 2026-01-29
CN115515573A (zh) 2022-12-23
IL296288B1 (en) 2024-02-01
US20230390231A1 (en) 2023-12-07
CO2022014343A2 (es) 2023-02-16
JP2023517566A (ja) 2023-04-26
IL309923A (en) 2024-03-01
AU2021233206A1 (en) 2022-10-06
MX2025012439A (es) 2025-11-03
US12433861B2 (en) 2025-10-07
US20210283080A1 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
MX2022011214A (es) Composiciones y metodos para el tratamiento de lesion por reperfusion o hemorragia despues de la terapia de recanalizacion.
MX2024010140A (es) Nuevos metodos.
MX2019012884A (es) Terapia de combinacion.
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
MX2021004110A (es) Composiciones farmaceuticas que comprenden n-(3,5- dimetoxifenil)-n'-(1-metiletil)-n-[3-(1-metil-1h- pirazol-4-il)quinoxalin-6-il]etano-1,2-diamina.
MX2018001193A (es) Compuestos de derivados de 1,3,4-oxadiazolsulfonamida como inhibidor de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos.
CY1125488T1 (el) Παραγωγα πυριδινης και θεραπευτικες χρησεις αυτων ως αναστολεις trpc6
CY1116511T1 (el) Μεθοδος αγωγης του κολπικου ινιδισμου
EP4306523A3 (en) Imidazoquinoline compounds and uses thereof
WO2021168483A3 (en) Treatment of human coronavirus infections using alpha-glucosidase glycoprotein processing inhibitors
MX2024009444A (es) Métodos de tratamiento para la fibrosis quística
MX2023000610A (es) Inhibidor de trpv4 como agente terapeutico para enfermedades oculares.
MX2023001014A (es) Composiciones farmaceuticas que comprenden venglustat.
AR048439A1 (es) Composiciones farmaceuticas y metodos para tratar la infeccion por vih
MX2023003332A (es) Inhibidores del elemento 1 interdispersado largo (line-1) para el tratamiento de enfermedades.
AR127533A1 (es) INHIBIDORES DEL SARS-CoV-2 PARA EL TRATAMIENTO DE INFECCIONES POR CORONAVIRUS
MX2022008216A (es) Tratamiento de cancer en combinacion usando un antagonista de pd-1, un antagonista de ilt4 y lenvatinib o sales del mismo.
MX2020005006A (es) Derivado de cumarina para terapia o profilaxis de un trastorno proliferativo celular.
JOP20250121A1 (ar) مشتقات ٢-أمينو-n-(٤-أمينو-٣، ٤-ديوكسو-١-(٢-أوكسو بيروليدين-٣-يل)بيوتان-2-يل)بنزاميد كمثبطات بروتياز لعلاج أو الوقاية من عدوي فيروس كورونا
CL2024003616A1 (es) Composición farmacéutica oral y uso para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas.
MX2022016406A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib.
ES2351665T3 (es) Derivados de benzamidina para el tratamiento y la prevención de mucositis.
DE602006017728D1 (de) Krebsbehandlung mittels fts und 2-deoxyglucose
AR129578A1 (es) MODULADORES DE LA ACTIVIDAD DE TNF-a
PA8579701A1 (es) Profarmaco inhibidor de beta-lactamasa